In LPV/r monotherapy, the on-treatment analysis indicates that a baseline HIV-1-RNA decrease in viral load at week 1, and HIV-1-RNA levels both at weeks 2 and 4 were predictive risk factors of the primary endpoint (P < 0.10, Table 3). Among these variables only early virological response at week 4 was an independent significant predictor of achieving the study primary endpoint. Thirty-seven of 41 patients (90.2%) with HIV-1 RNA less than 400 copies/ml at week 4 reached the primary endpoint.
There was no significant difference between the two groups with respect to the median change in the CD4 cell count from baseline to week 48 (P = 0.65). At week 48, the median change (interquartile range) was +151 (+105 to +239) and +159 (+112 to +250) cells/μl in the LPV/r monotherapy and LPV/r triple therapy arms, respectively.
Seventeen (20%) and 15 (28%) patients in the LPV/r monotherapy and LPV/r triple therapy arms, respectively, declared having missed at least two doses during the nine evaluations of the adherence from baseline to week 48. Overall, 34, 48 and 63% of patients who declared having missed none, one or more than two doses, respectively, had at least one low (< 3000 ng/ml) lopinavir trough concentration (test for trend, P = 0.003). Similarly, at least one undetectable value of lopinavir trough concentration was observed in 4, 6, and 22% of patients who declared having missed none, one or more than two doses, respectively (test for trend, P = 0.004). Plasma lopinavir trough concentrations were in the same range in the responder and in the non-responder groups in the monotherapy arm. No therapeutic change decisions were made in any of these patients based on plasma lopinavir concentrations.
Of the 24 patients who qualified for resistance testing, the majority (21/24) received LPV/r monotherapy. Protease inhibitor-associated resistance mutations emerged in three of 21 patients on LPV/r monotherapy (L76V, M46I). Phenotypic changes in lopinavir sensitivity were either not observed or were extremely modest ranging from a 1.13 to 2.69-fold increase compared with reference (Fig. 3). Trough plasma lopinavir concentrations were always above 3500 ng/ml in these three patients (Fig. 3). An NRTI-associated resistance mutation was seen in one of three patients on LPV/r triple therapy who required genotypic testing (M184V at week 24 in patient no. 5102); no patient on triple therapy developed protease inhibitor resistance mutations.
Ten of 83 patients (12%) on LPV/r monotherapy and four of 53 patients (8%) on LPV/r triple therapy experienced a serious adverse event throughout the study. None of the serious reported adverse events was considered to be related to study treatment by the investigator on site. Adverse events of at least moderate severity occurred with similar frequency in the two treatments groups. Diarrhoea was the most common clinical adverse event [five (6%) and four (8%) patients on LPV/r monotherapy and LPV/r triple therapy, respectively], whereas aspartate aminotransferase and alanine aminotransferase elevation was the most common laboratory abnormality [10 (12%) and four (8%) patients on LPV/r monotherapy and LPV/r triple therapy, respectively].
This is the first randomized trial comparing LPV/r monotherapy as a first-line regimen with a recommended potent triple regimen of zidovudine, lamivudine and LPV/r . In these antiretroviral-naive patients, using ITT-E analysis, 64% of patients randomly assigned reached the protocol-defined virological response in the LPV/r monotherapy arm compared with 75% in the LPV/r triple therapy arm. This difference was not statistically significant. The on-treatment analysis at week 48, however, shows a larger discrepancy between the two randomized groups with 80 and 98% of patients reaching the primary endpoint in the LPV/r monotherapy arm versus the LPV/r triple therapy arm. LPV/r monotherapy resulted in similar CD4 cell count increases as obtained with the standard triple drug combination. Patients on LPV/r monotherapy reported significantly fewer symptoms than those on triple combination.
In the LPV/r triple therapy arm, by ITT-E analysis, the percentage of patients with HIV-RNA levels below 50 copies/ml at week 48 (67%) is consistent with recent results involving antiretroviral-naive patients receiving two NRTI plus either boosted fosamprenavir  or boosted atazanavir . In our trial, the ITT-E analysis penalized the LPV/r triple therapy arm compared with the LPV/r monotherapy arm. At week 48, 16 and 23% of patients discontinued the study for any reason on LPV/r monotherapy and LPV/r triple therapy, respectively. Such a percentage on LPV/r triple therapy is concordant with results found in a recent trial also involving naive patients receiving a similar regimen . Therefore patients receiving LPV/r triple therapy were almost exclusively classified as non-responders as a result of discontinuation; whereas on LPV/r monotherapy, non-response resulted from a mixture of virological failures and discontinuations.
A higher proportion of intermittent viraemia (HIV RNA > 50 but < 400 copies/ml) was seen in the LPV/r monotherapy arm (Fig. 2), not only in this study with antiretroviral-naive patients, but also in maintenance studies in patients with previously undetectable viral loads [20,21]. Prolonged periods of low-level viraemia might favour the development of resistance mutations, as seen in the three patients on LPV/r monotherapy in our study, who developed resistance mutations after several weeks of almost continuous low-level viraemia (Fig. 3). The cause of these episodes of intermittent viraemia is not clearly understood at present. One possible explanation for the intermittent viraemia seen with LPV/r monotherapy is that in the absence of NRTI and their longer intracellular half-life, greater adherence may be required for constant suppression with LPV/r monotherapy. Of note is the fact that the median lopinavir trough concentration was similar between the two randomly assigned groups, although a limitation is that lopinavir trough measurements were recorded only at three timepoints. We observed, however, a correlation between the lopinavir trough concentration and self-reported adherence.
The long-term durability of the antiviral activity of LPV/r with two NRTI has been confirmed [11,12]. Studies with LPV/r in combination with two NRTI showed that the high inhibitory quotient of LPV/r at any time yields a plasma concentration of lopinavir that allows little replication of HIV [22–24]. Moreover, the high genetic barrier of LPV/r against resistance generally requires the accumulation of a high number of protease mutations to confer resistance . Additional mutations that were not present at baseline were detected in the protease gene in three of 83 patients (3.6%) on LPV/r monotherapy, and in the reverse transcriptase gene in one patient on LPV/r triple therapy up to week 48. The absolute risk of resistance over 48 weeks with LPV/r monotherapy does not appear to be high compared with triple non-nucleoside reverse transcriptase inhibitor-based therapy among antiretroviral-naive patients; however, it appears to be higher than has been observed with triple therapy protease inhibitor-associated resistance regimens [18,24]. The mutations selected yielded neither significant phenotypic nor genotypic resistance to LPV/r at the time of failure. In the context of this closely monitored clinical trial, however, the resistance observed does raise caution regarding any widespread usage of LPV/r monotherapy in an antiretroviral-naive population. Whether these results might be extended to the whole protease inhibitor-associated resistance drug class remains to be determined .
Importantly, in the LPV/r monotherapy arm, three patients (of which only one experienced a protocol-defined suboptimal response) were intensified with zidovudine and lamivudine, and all three achieved prolonged full viral suppression. This is in keeping with previous LPV/r maintenance therapy studies, in which most patients experiencing virological failure on LPV/r achieved full viral suppression with the addition of their previous NRTI backbone [20,21]. Therefore, in this study, virological failure on LPV/r monotherapy did not jeopardize future therapeutic options over the observed duration of follow-up. Long-term follow-up of LPV/r monotherapy patients will be required to assess the risks relative to resistance over time.
The limitations of this study include its open-label design, which might bias an assessment of tolerability or toxicity, but would be less likely to bias virological, immunological, or resistance endpoints. Another limitation may be the pilot nature of the study, with the limited power and the unbalanced sample size designed to focus on the LPV/r monotherapy arm. Finally, another limitation is that the study employed conservative entry criteria for both HIV-RNA level (< 100 000 copies/ml) and CD4 cell count (> 100 cells/μl). Therefore, results from this study may not be generalizable to the HIV-infected patient population as a whole.
Interestingly, 90% of patients randomly assigned to the LPV/r monotherapy group with HIV RNA below 400 copies/ml at week 4 reached the protocol-defined virological response. Therefore, an early decrease in the plasma viral load below 400 copies/ml might enable clinicians to predict potential responders to LPV/r monotherapy. We conclude that first-line monotherapy with LPV/r soft gel capsules is virologically less effective than the current standard-of-care triple combination with two NRTI and LPV/r soft gel capsules. Given the requirement for chronic therapy with current antiretroviral treatments, however, and the long-term toxicities associated with all antiretroviral therapies, long-term strategies that limit exposure while providing adequate virological efficacy deserve further study. Future monotherapy studies utilizing the more convenient LPV/r tablet formulation should focus on select patient populations, such as those with extensive reverse transcriptase inhibitor resistance (for example in developing countries where first to second-line switch is often driven by clinical failure and results in extensive NRTI resistance) . Taking into account the long-term rates of lipoatrophy, viral resistance, patient satisfaction and the cost of therapy are also critical to identify clinical scenarios in which LPV/r monotherapy might yet play a significant role in the treatment of HIV infection.
The authors wish to acknowledge the study participants and study staff at MDS Pharma Services, France. They are also grateful to the Independent Data Monitoring Committee (Jean Pierre Aboulker, Frederic Lucht, Marianne L'Henaff, Isabelle Pellegrin, Didier Sicard), and to Richard Rode, statistician, Abbott Laboratories.
Centre Hospitalier du Kremlin Bicetre: Jean-François Delfraissy, Cecile Goujard, Pascal Robquin, Yann Quertainmont, Olivier Segeral; Hopital Antoine Beclere, Clamart: François Boue, Veronique Chambrin, Gaelle-Anne Estocq, Isabelle Luquet-Besson, Carole Pignon; Hopital de l'Archet, Nice: Pierre Dellamonica, Francine De Salvador, Jacques Durand, Laurence Heripret, Veronique Rahelinirina; Hopital de la Conception, Marseille: Herve Gallais, F. Tomei, Herve Tissot Dupont, Isabelle Ravaux; Hopital Saint-Antoine, Paris: Pierre-Marie Girard, Diane Bollens, Franck Besse, Benedicte Lefebvre, Zineb Ouazene; Hopital Chalucet, Toulon: Alain Lafeuillade, Stephane Chadapaud, Gilles Hittinger; Hopital St Andre, Bordeaux: Philippe Morlat, Mojgan Bonarek, Marie-Carmen Pertusa, Caroline Nouts, Fabrice Bonnet; Hopital Haut Leveque, Pessac: Jean-Luc Pellegrin, Olivier Caubet, Caroline Perlemoine, Jean-François Viallard; Hopital Hotel Dieu, Nantes: François Raffi; Hopital Gui de Chauliac, Montpellier: Jacques Reynes, Vincent Baillat; Centre Hospitalier Intercommunal de Villeneuve Saint Georges: Olivier Patey, Sophie Dellion, Manuella Podani; Hopital Saint Joseph, Paris: Jacques Gilquin; Hopital Albert Michallon, Grenoble: Pascale Leclercq, Myriam Blanc; Hopital Saint Louis, Paris: Caroline Lascoux, Claire Pintado, Florence Vincent, Olivier Taulera; Hopital de Brabois, Vandoeuvre les Nancy: Thierry May, Christian Rabaud, Laurence Boyer, Thanh Lecompte; Hopital Ambroise Pare, Boulogne Billancourt: Elisabeth Rouveix; Centre Hospitalier Sud Francilien, Corbeil Essonnes: Alain Devidas, Pascale Kousignian, Pierre Chevojon; Hopital Delafontaine, Saint Denis: Marie-Aude Khuong, Nacira Khelil, Denis Mechali; Hopital Henri Mondor, Creteil: Yves Levy, Anne-Sophie Lascaux, Alain Sobel, Fabrice Chaix; Hopital de la Pitie-Salpetrière, Paris: Marc Antoine Valantin.
HIV Research and Clinical Care Centre, München: Hans Jäger, Andrea Eberhad, Eva Jägel-Guedes, Tim Theobald, Eva Wolf; Charité, Universitätsmedizin, Berlin: Dirk Schürmann, Thomas Wünsche, Hans Wesselmann; Klinik fur Gastroenterologie Hepatologie und Infektiologie, Düsseldorf: Mark Oette,Klaus Göbels, Stefanie Koch, Ruth Leidel, Arne Kroidl; EPIMED, Berlin: Keikawus Arastéh.
Osp. S. Raffaele, Milano: Adriano Lazzarin, Antonella Castagna, Nicola Gianotti; Az. Osp. Polo Universitario ‘L. Sacco’, Milano: Mauro Moroni, Antonella D'Arminio Monforte, Teresa Bini, Patrizia Biasi; Ospedale ‘Amedeo di Savoia’, Torino: Giovanni Di Perri, Stefano Bonora, Lorenzo Veronese, Laura Ladetto; A.O. Spedali Civili di Brescia, Brescia: Giampiero Carosi, Giusseppe Paraninfo, Paola Nasta; Univ. Degli Studi ‘La Sapienza’, Roma: Vincenzo Vullo, Anna Paola Massetti, Claudio Maria Mastroianni, Miriam Lichtner, Azzura Ginevra Miccoli.
Wojewodzki Szpital, Warszawa: Andrzej Horban, Piotr Pulik, Anna Ignatowska; Katedra I Oddzia, Wroc. Aw: Andrzej Gladyzs, Brygida Knysz, Jacek Gasiorowski.
Hospital Santa Creu, Barcelona: Pere Domingo, Montserrat Fuster, Mar Gutierrez, Gracia Mateo, Mercedes Gurgui, Ma Antonia Sambeat, Jose Cadafalch; Hospital Germans Trias, Badalona: Bonaventura Clotet, Angel Ballesteros, Jose Miranda, Jordi Puig Pla; Hospital San Jaume de Calella, Calella: Josep Ma Llibre, Silvia Valero.
Sponsorship: This study was sponsored by Abbott Laboratories.
Registration of randomized trial at clinicaltrials.gov under identifier NCT 00234923.
Conflicts of interest: None.
1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al
. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853–860.
2. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735–1744.
3. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112–1115.
4. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al
. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659–1667.
5. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309–1316.
6. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726–735.
7. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, et al
. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15:2441–2444.
8. Kahlert C, Hupfer M, Wagels T, Bueche D, Fierz W, Walker UA, Vernazza PL. Ritonavir boosted indinavir treatment as a simplified maintenance “mono”-therapy for HIV infection. AIDS 2004; 18:955–957.
9. Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, et al
. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806–814.
10. Campo RE, Lalanne R, Tanner TJ, Jayaweera DT, Rodriguez AE, Fontaine L, Kolber MA. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2005; 19:447–449.
11. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al
. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039–2046.
12. Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, Kessler HA, et al
. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004; 18:775–779.
13. Ebrahim O, Hill A. Short-course induction with boosted saquinavir monotherapy for naive patients with late-stage infection. AIDS 2005; 19:211–212.
14. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al
. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society – USA Panel. JAMA 2004; 292:251–265.
15. Hammer S, Saag M, Schechter M, Montaner J, Schooley R, Jacobsen D, et al
. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society – USA panel. JAMA 2006; 296:827–843.
16. Justice A, Holmes W, Gifford A. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001; 54:S77–S90.
17. WHOQOL. HIV for quality of life assessment among people living with HIV and AIDS: results from the field test.AIDS Care
18. Eron J Jr, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, et al
. The KLEAN study of fosamprenavir–ritonavir versus lopinavir–ritonavir, each in combination with abacavir–lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised noninferiority trial. Lancet 2006; 368:476–482.
19. Malan N, Krantz E, David N, Kastango K, Frederick D, Matthew M, et al
. Efficacy and safety of atazanvir-based therapy in antiretroviral naive HIV-1 infected patients, both with or without ritonavir: 48-week results from AI24-089. In: 13th Conference on Retroviruses and Opportunistic Infections
. Denver, CO, USA; 5–8 February 2006. Abstract 107 LB.
20. Cameron W, da Silva B, Arribas J, Myers R, Bellow N, Gillmore N, et al
. A two-year randomized controlled clinical trial in antiretroviral-naive patients using lopinavir/ritonavir (LPV/r) monotherapy after initial induction treatment compared to an efavirenz (EFV) 3-drug regimen (Study M03-613). In: XVIth International AIDS Conference
. Toronto, Canada; 13–18 August 2006. Abstract THLB0201.
21. Arribas J, Pulido F, Delgado R, Lorenzo A, Miralles P, Arrantz A, et al
. Lopinavir/ritonavir as single-drug maintenance therapy in patients with HIV-viral suppression: forty eight week results of a randomized, controlled, open label, clinical trial (OK04 study). In: XVIth International AIDS Conference
. Toronto, Canada; 13–18 August 2006. Abstract THLB0203.
22. King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis 2005; 191:2046–2052.
23. Mo H, King MS, King K, Molla A, Brun S, Kempf DJ. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected patients failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol 2005; 79:3329–3338.
24. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, et al
. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51–60.
25. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, et al
. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75:7462–7469.
26. Karlström O, Josephson F, Sönnerborg A. Early virological rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr 2007; 44:417–422.
27. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447–452.
Keywords:© 2008 Lippincott Williams & Wilkins, Inc.
Cost; HIV; long-term complications; lopinavir; monotherapy; protease inhibitors